By Sheeba M. | April 21, 2026
Trump’s Psychedelics Order May Have Just Unlocked the Door for Cannabis Rescheduling
When President Trump signed an executive order on psychedelics research this past Saturday, most cannabis investors yawned. Wrong move. The order — directing the FDA to expand clinical trials for psilocybin, MDMA, and ibogaine — is a two-pronged political signal that could accelerate the stalled cannabis rescheduling timeline.
Why the Psychedelics Order Matters for Cannabis
The key insight: psychedelics advocates have spent decades fighting the same scheduling battle cannabis operators face. The same lawyers, the same policy advocates, the same Congressional coalition. When Trump signs an order that says “we’re moving forward on drug policy reform,” it creates a cascade effect across the entire reform ecosystem.
Shawn Hauser, partner at cannabis law firm Vicente LLP, noted that the order reflects a broader Washington shift toward a medical-first framework — one that provides a procedural roadmap for cannabis to follow. “The process has certainly been slow and frustrating for stakeholders when you consider they have spent decades fighting marijuana’s outrageous 1970s-era misclassification,” Hauser told CNBC.
The practical implication: agencies that were slow-walking cannabis reviews now have explicit White House cover to move faster. The DEA has less political runway to delay.
Who Benefits Most: A Tier-by-Tier Breakdown
Tier 1 — Direct beneficiaries with Florida exposure: Trulieve (TCNNF) is the most direct play on accelerated federal reform. Florida’s adult-use market is already live, and a Schedule III ruling removes the banking restriction that forces Trulieve to operate on cash-only rails in many markets. Watch TCNNF closely ahead of its May 7 earnings call.
Tier 2 — Multi-state operators with clean balance sheets: Green Thumb Industries (GTBIF) has $200M+ in cash and generates positive EBITDA. The 280E relief scenario adds an estimated $50M to pre-tax income — a re-rating catalyst that the current valuation completely ignores. GTBIF is the institutional-quality name in this group.
Tier 3 — Canadian LPs with US exposure: Canopy Growth (CGC) remains a value trap — but a rescheduling catalyst changes the math on any US M&A pipeline it has been building. Speculative, but worth monitoring.
The Stock Reaction Tells You Everything
The psychedelics angle is already moving stocks. Atai Life Sciences (ATAI) jumped 25% Monday on the order. Smaller-cap psychedelic plays rallied in sympathy. The question for cannabis MSOs is whether that same institutional demand shows up — and the early read is that it is. Curaleaf (CURLF) and GTBIF both saw elevated volume the day of the order.
If you’re not positioned in Green Thumb Industries (GTBIF) or Trulieve (TCNNF) ahead of a potential DEA movement signal, you’re watching the move from the sidelines. The risk-reward here favors being early.
Sources
- CNBC – How Trump’s Psychedelics Executive Order Could Unlock Stalled Cannabis Reform — Federal process analysis, Vicente LLP perspective
- INN – Cannabis Market Transition: 4/20 Reality Check — Political landscape and 280E impact analysis
- Trulieve PR – Tallahassee Dispensary Opening — April 20th expansion milestone
Track cannabis stocks with the Weedstock Real-Time Tracker